Durvalumab's FDA-approval for NSCLC and the supporting PACIFIC study are discussed, then the ASCO Immunotherapy Toxicity Management Guidelines (7:45) are reviewed. Also, a plug for patient support groups.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
